Репозиторий Винницкого национального медицинского университета имени Н. И. Пирогова

Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double - blind randomised controlled trial

Показать сокращенную информацию

dc.contributor.author Vestbo, J. en
dc.contributor.author Anderson, J. A. en
dc.contributor.author Brook, R. D. en
dc.contributor.author Calverley, P. M. A. en
dc.contributor.author Celli, B. R. en
dc.contributor.author Crim, C. en
dc.contributor.author Martinez, F. en
dc.contributor.author Yates, J. en
dc.contributor.author Newby, D. E. en
dc.contributor.author Abrahamovych, O. en
dc.contributor.author Amer, L. en
dc.contributor.author Berenfus, V. en
dc.contributor.author Biloglazov, V. en
dc.contributor.author Bilokonna, N. en
dc.contributor.author Blazhko, V. en
dc.contributor.author Borovyk, V. en
dc.contributor.author Boyko, M. en
dc.contributor.author Butvyn, S. en
dc.contributor.author Chopey, I. en
dc.contributor.author Dudchenko, L. en
dc.contributor.author Dziublyk, O. en
dc.contributor.author Feshchenko, Y. en
dc.contributor.author Fushtey, I. en
dc.contributor.author Gavrysyuk, V. en
dc.contributor.author Godlevska, O. en
dc.contributor.author Golovchenko, N. en
dc.contributor.author Golovchenko, O. en
dc.contributor.author Grishyna, O. en
dc.contributor.author Gyrina, O. en
dc.contributor.author Hospodarskyy, I. en
dc.contributor.author Iabluchanskyi, M. en
dc.contributor.author Iashyna, L. en
dc.contributor.author Kaidashev, I. en
dc.contributor.author Kazymyrko, V. en
dc.contributor.author Khomazyuk, T. en
dc.contributor.author Khvelos, S. en
dc.contributor.author Knopyk, L. en
dc.contributor.author Kopytsya, M. en
dc.contributor.author Korzhevnyk, I. en
dc.contributor.author Koshukova, G. en
dc.contributor.author Kovalchuk, T. en
dc.contributor.author Krakhmalova, O. en
dc.contributor.author Krasnokutskiy, S. en
dc.contributor.author Krasyuk, S. en
dc.contributor.author Kulyk, A. en
dc.contributor.author Kulynych, O. en
dc.contributor.author Kuryata, O. en
dc.contributor.author Levchenko, O. en
dc.contributor.author Monogarova, N. en
dc.contributor.author Mostovoy, Y. en
dc.contributor.author Nalotov, S. en
dc.contributor.author Ospanova, T. en
dc.contributor.author Ostrovskyy, M. en
dc.contributor.author Panina, S. en
dc.contributor.author Pasiyeshvili, L. en
dc.contributor.author Pavlyk, S. en
dc.contributor.author Pertseva, T. en
dc.contributor.author Plesh, I. en
dc.contributor.author Prystupa, L. en
dc.contributor.author Rodionova, V. en
dc.contributor.author Romaniuk, I. en
dc.contributor.author Shvets, N. en
dc.contributor.author Skrypnyk, I. en
dc.contributor.author Stanislavchuk, M. en
dc.contributor.author Stets, R. en
dc.contributor.author Synenko, V. en
dc.contributor.author Syvolap, V. en
dc.contributor.author Teliatnikova, Z. en
dc.contributor.author Tovt-Korshynska, M. en
dc.contributor.author Vatutin, M. en
dc.contributor.author Vayda, M. en
dc.contributor.author Vishnivetsky, I. en
dc.contributor.author Vizir, V. en
dc.contributor.author Voloshyna, O. en
dc.contributor.author Vynnychenko, L. en
dc.contributor.author Yagensky, A. en
dc.contributor.author Yatsyshyn, R. en
dc.contributor.author Zharinova, V. en
dc.contributor.author Zhebel, V. en
dc.date.accessioned 2017-10-16T15:58:40Z
dc.date.available 2017-10-16T15:58:40Z
dc.date.issued 2016
dc.identifier.citation Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double - blind randomised controlled trial / J. Vestbo, J. A. Anderson, R. D. Brook [et al.] // The Lancet. - 2016. - Vol. 387, № 10030. - P. 1817-1826. en
dc.identifier.uri https://dspace.vnmu.edu.ua/123456789/1045
dc.description.abstract Chronic obstructive pulmonary disease (COPD) often coexists with cardiovascular disease. Treatments for airflow limitation might improve survival and both respiratory and cardiovascular outcomes. The aim of this study was to assess whether inhaled treatment with a combined treatment of the corticosteroid, fluticasone furoate, and the long-acting β agonist, vilanterol could improve survival compared with placebo in patients with moderate COPD and heightened cardiovascular risk. en
dc.language.iso en en
dc.publisher The Lancet en
dc.subject chronic obstructive pulmonary disease en
dc.subject atherosclerotic cardiovascular disease en
dc.subject randomised controlled trial en
dc.title Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double - blind randomised controlled trial en
dc.type Other en


Файлы в этом документе

Данный элемент включен в следующие коллекции

Показать сокращенную информацию

Поиск в DSpace


Просмотр

Моя учетная запись

Статистика